Medlab Clinical Ltd.

Netcapital

Agape ATP

Tradr 2X Long QBTS Daily ETF

Akanda

Defiance Daily Target 2X Long RGTI ETF

PicoCELA

Tradr 2X Long RGTI Daily ETF

Co-Diagnostics

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NewGenIvf

LABU

MDLB

Medipharm Labs held its Q4 earnings call, reporting a full-year revenue of $45.1 million, an 8% increase year-over-year, marking a five-year high. International medical cannabis grew 43%, becoming the primary revenue source. Despite narrowing losses, the company remains unprofitable, with an $8.3 million net loss. Operating expenses decreased by 14%, and the company has a strong balance sheet with $10.8 million in cash and no debt. Q4 revenue fell to $11.1 million, highlighting volatility, but management remains optimistic about future growth and expansion into international markets.

Tip Ranks

iShares Global Healthcare

Direxion S&P Biotech Bull 3X

iShares US Medical Devices

iShares US Pharma

Invesco Biotechnology & Genome ETF

Health Care Select Sector SPDR

iShares Biotechnology ETF

First Trust NYSE Arca Biotech Index Fd

VG Health

ALPS Medical Breakthrough

VanEck Biotech ETF

Prophase Labs

SPDR S&P Biotech

Proshares Ultra Nasdaq Biotech

Ark Genomic Revolution ETF

iShares Genomics Immunology and Healthcare ETF

iShares US Healthcare Providers

Medipharm Labs Earnings Call Highlights Global Growth Pivot

LabConnect has launched SampleGISTICS® 2.0, a smartphone-based application designed to digitize sample collection in clinical trials. This new solution replaces outdated digital pen technology, streamlining workflows and providing real-time visibility of samples. It aims to eliminate paper requests and manual data entry, reducing sample loss and delays. The app features barcode scanning, multilingual support, and offline functionality, enhancing data collection and compliance. SampleGISTICS 2.0 offers guided workflows aligned with study protocols, improving data accuracy and facilitating faster lab results. LabConnect specializes in centralized laboratory services for clinical trials.

prnewswire

10:49 ETLabConnect lanza SampleGISTICS® 2.0 para digitalizar la captura de muestras en ensayos clínicos

BIOLQ

BioLab Holdings has earned the Great Place to Work® certification, reflecting its commitment to a positive workplace culture based on employee feedback. Key findings include 90% of employees feeling treated fairly, 96% affirming physical safety, and 92% confident in service quality. The certification highlights BioLab's focus on inclusion, transparency, and ethical leadership, positioning it as an employer of choice in the life sciences sector. The company plans to continue improving through employee insights and regular feedback surveys.

BIOLASE INC

15:05 ETBioLab Holdings Earns Great Place to Work® Certification

MDCX

MediPharm Labs Corp. reported FY 2025 revenue of $45.1 million, an 8% increase from 2024, with international medical cannabis revenue rising 43% year-over-year, making up over 50% of total revenue. The company ended Q4 with a cash balance of $10.8 million and remains virtually debt-free. MediPharm plans to expand its product portfolio and geographic reach, targeting markets like Brazil, France, and New Zealand. A conference call to discuss the financial results is scheduled for March 30, 2026.

GlobeNewswire

Medicus Pharma

MediPharm Labs Reports Full Year & Fourth Quarter 2025 Results with Over 40% Annual Growth in International Medical Revenue

Latent Labs has introduced Latent-Y, an AI agent that can create therapeutic antibodies quickly from text prompts. This technology uses Latent-X2, the company's advanced model for antibody and peptide design, to accelerate the process significantly. By leveraging Latent-Y, researchers can now achieve in hours what would typically take weeks with expert input. This innovation enables structural drug design without needing specialized infrastructure, broadening access for all researchers. Latent Labs is partnering with selected organizations to provide access to Latent-Y, which promises to revolutionize drug discovery.

Unusual Whales

Latent-Y: The Autonomous AI Agent for Drug Design at Scale

MediPharm Labs Sets March 30 Date for 2025 Results and Investor Call

MediPharm Labs Sets March 30 Date for 2025 Results and Investor Call

WCGC

NutraBrain Clinic, a recently established telehealth platform by Dr. David Mahjoubi, a board-certified anesthesiologist, offers physician-monitored ketamine treatment to eligible patients across various American states. The service caters to individuals who have been assessed and approved as suitable candidates for at-home care.

WCG CLINICAL INC

Los Angeles Board-Certified Anesthesiologist Dr. David Mahjoubi Launches NutraBrain Clinic Telehealth Platform for Physician-Supervised Ketamine Care

Medlab Clinical Ltd.(MDLB.US)

Medipharm Labs Earnings Call Highlights Global Growth Pivot

10:49 ETLabConnect lanza SampleGISTICS® 2.0 para digitalizar la captura de muestras en ensayos clínicos

15:05 ETBioLab Holdings Earns Great Place to Work® Certification

MediPharm Labs Reports Full Year & Fourth Quarter 2025 Results with Over 40% Annual Growth in International Medical Revenue

Latent-Y: The Autonomous AI Agent for Drug Design at Scale

MediPharm Labs Sets March 30 Date for 2025 Results and Investor Call

Los Angeles Board-Certified Anesthesiologist Dr. David Mahjoubi Launches NutraBrain Clinic Telehealth Platform for Physician-Supervised Ketamine Care